Matthew Hevey, MD
Infectious Disease · Colorado Springs, CONPI 1356769590
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (48.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Gilead accounts for 77.0% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2023 at $5,472 and has fallen 90.8% since, to $505 in 2025. Among infectious disease clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 131 payments — averaging $58.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$6K
- Viiv Healthcare Company$881
- Merck$271
- AbbVie$185
- Astellas Pharma US Inc$66
- Shionogi Inc$48
- plus $314 from 11 others
What the payments were for
- Consulting fees$3,75049%
- Travel & lodging$1,12515%
- Food & beverage$2,77836%
- Education$260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 46 | $5,915 |
| Viiv Healthcare Company | 41 | $881 |
| Merck | 13 | $271 |
| AbbVie | 10 | $185 |
| Astellas Pharma US Inc | 3 | $66 |
| Shionogi Inc | 2 | $48 |
| AstraZeneca | 2 | $45 |
| Ferring Pharmaceuticals Inc. | 2 | $44 |
| Johnson & Johnson | 2 | $41 |
| La Jolla Pharmaceutical Company | 2 | $34 |
| Tetraphase Pharmaceuticals, Inc. | 2 | $33 |
| Vyera Pharmaceuticals, LLC | 1 | $21 |
| Insmed, Inc. | 1 | $21 |
| Melinta Therapeutics, LLC | 1 | $21 |
| Aimmune Therapeutics, Inc. | 1 | $20 |
| Ossur Americas, Inc. | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DOVATO$113
How this compares
$7,679 in reported general payments places this provider in the 90th percentile of 146 infectious disease providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 42 | $201,799 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 12 | $51,001 |
| JulucaDolutegravir/Rilpivirine | 14 | $49,428 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 13 | $44,276 |
| DovatoDolutegravir Sodium/Lamivudine | 13 | $36,374 |
| Daptomycin | 13 | $13,498 |
| Ampicillin Sodium | 12 | $5,217 |
| CeftriaxoneCeftriaxone Sodium | 58 | $3,957 |
| Cefadroxil | 42 | $3,832 |
| ErtapenemErtapenem Sodium | 13 | $2,084 |
| Cefazolin Sodium | 22 | $1,385 |
| Ampicillin-SulbactamAmpicillin Sod/Sulbactam Sod | 19 | $1,222 |
| Doxycycline Hyclate | 36 | $1,048 |
| Vancomycin Hcl | 11 | $894 |
| Cephalexin | 36 | $600 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy | $5,915 | $201,79942 claims |
| Viiv Healthcare CompanyTriumeq, Juluca, Dovato | $881 | $136,80339 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 146 infectious disease providers in Colorado.
Other infectious disease in Colorado Springs
- Peter BrookmeyerColorado Springs$3K
- Carl Allen BernasColorado Springs$3K
- Elizabeth KleinerColorado Springs$3K
- Thomas HackenbergColorado Springs$2K
- Robert GatesColorado Springs$945
- Robert WeberColorado Springs$386
- David GriffithDenver$252K
- Kenneth GreenbergDenver$163K
- Shannon KasperbauerDenver$94K
- Kristine ErlandsonAurora$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.